Cardinal Health, Inc. (CAH) Shares Gain Favor as Citi Turns Bullish on Specialist Assets

We recently compiled a list of the 10 Best Investments During A Recession. Cardinal Health, Inc. is one of the best investments on our list.

TheFly reported on January 9 that Citi upgraded CAH from Neutral to Buy, raising the price target from $190 to $244. Daniel Grosslight, a Citi analyst, offered this upgrade, which shows confidence in the company’s growth of specialist assets in addition to the solid performance of its main pharmaceutical distribution business.

Citi highlighted further expansion of the specialist business of Cardinal Health, Inc. (NYSE:CAH), especially the addition of newly acquired MSO assets such as Solaris Health, which is expected to enhance the efficiency of operations and aid in the increase of revenue. It was announced that the company remains cautious on the Global Medical Products and Distribution (GMPD) business, although it believes that the potential upside exists compared to its own expectation versus the consensus forecasts.

Cardinal Health, Inc. (NYSE:CAH) is a large U.S. healthcare services and products company headquartered in Dublin, Ohio. It distributes pharmaceuticals and medical supplies to hospitals, pharmacies, and clinics globally, and manufactures medical and surgical products. The business operates in two segments: Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution.

While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.